All results

12 results for risk and resilience during covid 19

• TN-31 JAKPOT T1D

  A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…

  Ages

  12 Years - 35 Years

  Sexes

  All

• Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST

  This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…

  Ages

  12 Years - 99 Years

  Sexes

  All